Antral Follicle Priming Before Intracytoplasmic Sperm Injection in Previously Diagnosed Low Responders: A Randomized Controlled Trial (FOLLPRIM)

作者：Marzal Escriva Alicia; Diaz Garcia Cesar^*; Monterde Mercedes; Maria Rubio Jose; Pellicer Antonio

来源：Journal of Clinical Endocrinology & Metabolism, 2015, 100(7): 2597-2605.

DOI：10.1210/jc.2015-1194

Context: A low response to controlled ovarian hyperstimulation implies a reduced number of embryos and impaired pregnancy rate. Follicular priming with steroids before controlled ovarian hyperstimulation has been suggested to improve the subsequent ovarian response.
Objective: Thepurposeofthisstudywastodeterminethebestfollicularprimingprotocolinlowresponders and to investigate the intrafollicular mechanisms triggered by steroid hormone priming.
Design: This was a single-center, randomized, parallel, open-label, controlled trial, in two phases.
Setting: The setting was a university-based in vitro fertilization unit.
Patients: Potential low responders (n = 99) underwent a first intracytoplasmic sperm injection cycle. Confirmed low responders (n = 66) were randomized to different priming protocols before a new intracytoplasmic sperm injection.
Interventions: Randomized patients underwent one of the following priming strategies: transdermal testosterone (20 mu g/kg/d), transdermal estradiol (200 mu g/d), orcombinedestrogensandoral contraceptive pills (30 mu g of ethinyl estradiol plus 150 mu g of desogestrel administered during the luteal phase of two consecutive cycles) and 4 mg/d of estradiol valerate during the follicular phase between them.
Main Outcomes Measures: Metaphase II (MII) oocytes were retrieved. Gene expression levels in the granulosa cells of steroidogenesis enzymes and FSH, LH, and androgen receptors were measured.
Results: The number of retrieved MII oocytes did not differ between the interventional groups (testosterone, 2.2 +/- 2.0; estrogen, 2.7 +/- 1.7; and combined estrogens and oral contraceptive pills, 2.0 +/- 1.3; not significant). Compared with those in nonprimed cycles, estradiol pretreatment yielded more MII oocytes (primed, 2.7 +/- 1.7; nonprimed, 1.6 +/- 1.2; P = .029) although the clinical pregnancy rate was higher in patients treated with testosterone (P = .003). Testosterone pretreatment increased androgen receptor expression (P = .028) compared with that for the previous cycle without priming.
Conclusions: The results of the present trial do not support the superiority of one priming strategy over the others.

• 出版日期2015-7